Vesicare brings hope to Astellas as it looks to post-Prograf future
This article was originally published in Scrip
Executive Summary
The main take-away from Astellas' first-half results was the steady rise of the overactive bladder drug Vesicare (solifenacin), which is helping to soften the blow from the loss of exclusivity for the firm's long-time top product Prograf (tacrolimus).